Skip to main content

Advertisement

SpringerLink
Log in

Burden of illness in chronic inflammatory demyelinating polyneuropathy: some clarifications

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Querol L, Crabtree M, Herepath M, et al (2020) Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol (in press)

  2. Rajabally YA, Afzal S (2019) Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol 266:461–467

    Article  Google Scholar 

  3. Mahdi-Rogers M, Mccrone P, Hughes RAC (2014) Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol 21:34–39

    Article  CAS  Google Scholar 

  4. Lunn MP, Ellis L, Hadden RD et al (2016) A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 21:33–37

    Article  CAS  Google Scholar 

  5. Kuitwaard K, Fokkink WJR, Brusse E et al (2017) Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 138:1328–1336

    Google Scholar 

  6. Adrichem ME, Eftimov F, van Schaik IN (2016) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. J Peripher Nerv Syst 21:121–127

    Article  CAS  Google Scholar 

  7. Kapoor M, Spillane J, Englezou C et al (2020) Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy. Neurology 94:e635–e638

    Article  Google Scholar 

  8. Broers MC, Doorn PA, Kuitwaard K, et al (2020) Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: a survey among Dutch neurologists. J Peripher Nerv Syst (in press)

  9. Group RMCT (2009) Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 8:158–164

    Article  Google Scholar 

Download references

Acknowledgments

Funding for the original study to which this scientific letter replies was provided by CSL BEHRING GmbH. The authors thank Dr Nick Leach for providing medical writing and editorial support, which was funded by CSL BEHRING GmbH in accordance with Good Publication Practice (GPP3) guidelines.

Author information

Authors and Affiliations

  1. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    L. Querol

  2. Huron Consulting Group, London, UK

    M. Crabtree, E. Priedane & S. Agush

  3. Optimal Access Life Science Consulting Limited, Swansea, UK

    M. Herepath

  4. CSL Behring, Hattersheim, Germany

    I. Viejo-Viejo & P. Sommerer

Authors
  1. L. Querol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Crabtree
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Herepath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Priedane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Viejo-Viejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Agush
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Sommerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Querol.

Ethics declarations

Conflicts of interest

LQ has provided expert testimony for Grifols, Sanofi-Genzyme, Novartis, UCB, Roche, and CSL Behring, and received research funds from Novartis Spain, Sanofi-Genzyme, and Grifols. MC, EP, and SA are, or were, employees of Huron Consulting Group. Huron Consulting Group received funding from CSL Behring GmbH to perform the study. IV and PS are, or were, employees of CSL Behring GmbH. MH is an employee of Optimal Access Life Science Consulting Limited and received funding from CSL Behring.

Ethical standards

This article does not include studies with animals or human participants performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Querol, L., Crabtree, M., Herepath, M. et al. Burden of illness in chronic inflammatory demyelinating polyneuropathy: some clarifications. J Neurol 267, 3094–3095 (2020). https://doi.org/10.1007/s00415-020-10115-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-020-10115-y

Search

Navigation